President Donald Trump revealed that Becton, Dickinson and Company, or BD, a US medical technology company, plans to invest $3 billion to expand production of essential medical products within the United States, amid the US government's efforts to push companies to move healthcare product manufacturing back into the country. Of that total, more than $1 billion will be used in Nebraska to expand BD's production of medical products, including needles made from US steel, covering syringes, needles and other medical products. The White House said BD will invest $110 million to expand production of prefilled syringes at its plant in Columbus, Nebraska, which is expected to create about 120 jobs and is an additional investment on top of the $35 million the company previously invested in this plant. Trump said the investment is tied to the US government's plan to impose tariffs on medical equipment, which is expected to take effect by the end of this year. BD, one of the world's largest medical technology companies, is restructuring its business this year after completing the spin-off of its Biosciences and Diagnostic Solutions unit into the company Waters in February.
Becton Dickinson and CompanyBD plans a $3 billion US investment to expand medical device production, including $1B+ in Nebraska and $110M for prefilled syringes in Columbus.
Waters Corporation